· The Thiazolidiendiones, i.e. Rosiglitazone and Pioglitazone have been now accepted as successful PPARα agonists, and are being marketed as drugs to treat Type II diabetes.1
· Derivatives of Pyrazole-4-carboxylic acid and Pyridine-3-propanoic acid have been reported to be an important breakthrough in the design of structurally new compounds as potential therapeutics for the treatment of Type II diabetes.
· A novel series of 2, 3-disubstituted indole-5-phenylacetic acid derivatives, and indole propionic acids as novel PPARa/c co-agonists that function as selective PPARγ agonists in vitro has been reported describing the structural activity relationship of indole derivatives for possessing agonist activity for PPARγ receptors.
· Indanylacetic acid group has been reported as a versatile head-group, which can be combined to diverse tail groups to generate PPAR agonists with different receptor subtype selectivity.
· In 2004, which is claimed to be a dual-agonist to PPARα & γ. Bristol-Myers Squibb Company announced that the company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for Muraglitazar, an investigational agent under development for the treatment of patients with type 2 diabetes.
